Yunu CEO Advocates For Enhanced Imaging Workflow In Clinical Trials

At the recent LSI Emerging Medtech Summit, Yunu CEO Jeff Sorenson took center stage to address the critical challenges facing clinical trial imaging today. In a compelling afternoon session, Sorenson shed light on the pivotal role of imaging in clinical trials and introduced the transformative impact of Yunu's cloud platform technology on drug discovery processes. The discussion underscored the pressing issues of workflow inefficiencies, staffing shortages, and outdated systems at research sites, which contribute to significant image assessment error rates ranging from 25% to 50%.

Sorenson articulated how these challenges not only hinder the enrollment of suitable patients but also lead to protocol violations and discrepancies between sites and central review, ultimately affecting patient treatment and trial outcomes. He emphasized, "The state of affairs in clinical trial imaging is at odds with industry initiatives for increasing diversity, broadening access, and improving trial outcomes." Yunu's innovative approach aims to address these issues by fostering a seamless connection between sponsors, CROs, imaging CROs, and research sites.

Yunu's cloud-based ecosystem is designed to enhance workflow efficiency and extend trial access while boosting visibility for sponsors and CROs. The platform currently manages over 4,200 active clinical trials and has garnered attention from prestigious institutions including a nationwide cancer center, a professional medical society imaging core lab, and a leading children's research hospital. This ecosystem facilitates real-time data access for stakeholders, enabling earlier decision-making and more effective data science initiatives that lead to impactful trial outcomes.

"Well-orchestrated imaging workflow that efficiently accomplishes all of the required complex measurements, calculations, tracking, and signoffs is key to creating a future where prospective source data is accurately captured, labeled, and widely available," Sorenson stated. He further highlighted the importance of clean and complete data as a prerequisite for leveraging AI in drug development.

Yunu is at the forefront of medical research technology, offering services to life sciences companies and clinical research environments focused on precision imaging assessments. The company's mission is to make breakthrough therapies accessible to everyone by unifying medical imaging insights and connecting clinical communities. With its platform supporting thousands of clinical trials daily, Yunu is setting a new standard for clinical trial imaging workflow efficiency. For more information about Yunu and its services, visit https://www.yunu.io.